Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
BMJ Open. 2021 Jul 2;11(7):e042856. doi: 10.1136/bmjopen-2020-042856.
We aimed at developing a patient-centred self-help programme, tailored to the needs of patients with rare chronic diseases.
Multistage, multimethod development process including a survey with validated self-report scales and open-ended questions (phase 1) and focus groups (phase 2) for needs assessment and, consolidating the first phases and the literature, the intervention development (phase 3).
Phase 1: nationwide online survey in Germany, phase 2: four separate and diagnostically homogeneous focus groups. The focus groups took place at a university medical centre in Germany.
Target group were patients with rare diseases that occur at a prevalence <1:2000. Phase 1: n=300 participants with different rare diseases. Phase 2: Individuals with neurofibromatosis type 1 (n=4), primary sclerosing cholangitis (n=5), pulmonary arterial hypertension (n=4) and Marfan syndrome (n=5).
The central results of phases 1 and 2 were requests for more information about the disease and contact with other affected persons. Patients also expressed support needs in dealing with difficult emotions and identified acceptance of the disease as a turning point for quality of life. In phase 3, we identified acceptance and commitment therapy (ACT) as a suitable therapeutic approach and determined details about implementation and execution of self-management programmes. A 6-week self-help concept led by peer counsellors was developed, which includes disease-specific information and ACT-based exercises.
Based on a multistage needs assessment, we developed a peer-guided self-help intervention for patients with rare chronic diseases. Combining self-management, peer-counselling and ACT may help living with a rare condition. Further research needs to test the programme's efficacy.
ISRCTN13738704.
我们旨在开发一种以患者为中心的自助计划,以满足罕见慢性疾病患者的需求。
包括使用经过验证的自我报告量表和开放式问题进行的多阶段、多方法开发过程(第 1 阶段)和焦点小组(第 2 阶段)进行需求评估,并整合第一阶段和文献,进行干预措施的开发(第 3 阶段)。
第 1 阶段:德国全国范围的在线调查;第 2 阶段:四个单独的、具有诊断同质性的焦点小组。焦点小组在德国一所大学医学中心进行。
目标人群为患病率<1:2000 的罕见疾病患者。第 1 阶段:n=300 名患有不同罕见疾病的参与者。第 2 阶段:神经纤维瘤病 1 型(n=4)、原发性硬化性胆管炎(n=5)、肺动脉高压(n=4)和马凡综合征(n=5)的个体。
第 1 阶段和第 2 阶段的主要结果是需要更多有关疾病的信息和与其他受影响者的联系。患者还表示在处理困难情绪方面需要支持,并将接受疾病作为生活质量的转折点。在第 3 阶段,我们确定了接纳与承诺疗法(ACT)作为一种合适的治疗方法,并确定了实施和执行自我管理计划的细节。开发了一种由同伴辅导员领导的为期 6 周的自助概念,其中包括特定于疾病的信息和基于 ACT 的练习。
基于多阶段需求评估,我们为罕见慢性疾病患者开发了一种同伴指导的自助干预措施。将自我管理、同伴咨询和 ACT 相结合,可能有助于应对罕见疾病。需要进一步的研究来测试该计划的疗效。
ISRCTN81234444。